Pharmaceutical Executive

In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo for adults with relapsed or refractory follicular lymphoma, and Alnylam announces a $250 million investment in a new Massachusetts manufacturing facility.

In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 billion licensing agreement with Jacobio Pharma for a pan-KRAS inhibitor, and BioMarin enters a definitive $4.8 billion agreement to acquire Amicus Therapeutics.

In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (ESG) goals are shaping the organization's next phase of growth—particularly as demand surges for its GLP-1 products Zepbound and Mounjaro. From access and affordability to supply chain expansion and climate commitments, Greffet discusses the importance of establishing ESG as a core business driver for manufacturers—and key component to long-term operational strategy and thinking.

In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for biopharma supply chains, and industry experts examine how rebate consultants are shaping biosimilar adoption.

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collaboration and merger activity highlights continued dealmaking momentum across biopharma.

In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s disease and B-cell depletion, and the agency issues a national priority voucher tied to Tecvayli in multiple myeloma.

In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.

In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novartis form a $1 billion multi-program collaboration targeting atopic diseases, and new insights reveal how payers are shaping expectations for Phase III trial design.